145 related articles for article (PubMed ID: 31853972)
41. [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia].
Božić M; Bojović K; Fabri M; Nožić D; Trkulja B; Milošević I
Srp Arh Celok Lek; 2012; 140(7-8):448-55. PubMed ID: 23092029
[TBL] [Abstract][Full Text] [Related]
42. Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.
Abd-Elsalam S; Badawi R; Elnawasany S; Yousef M; Mansour L; Hawash N; Elkhouly RA; Soliman S; Selim A; Kobtan A; Elfert A
Infect Disord Drug Targets; 2019; 19(2):179-184. PubMed ID: 30207250
[TBL] [Abstract][Full Text] [Related]
43. Impact of IFNL4 rs12979860 and rs8099917 polymorphisms on response to Peg-Interferon-α and Ribavirin in patients with congenital bleeding disorder and chronic hepatitis C.
Keshvari M; Alavian SM; Behnava B; Pouryasin A; Craig JC; Sharafi H
J Clin Lab Anal; 2017 Jul; 31(4):. PubMed ID: 27735085
[TBL] [Abstract][Full Text] [Related]
44. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
Nyberg L; Albrecht J; Glue P; Gianelli G; Zambas D; Elliot M; Conrad A; McHutchison J
J Clin Gastroenterol; 1999 Jun; 28(4):313-6. PubMed ID: 10372927
[TBL] [Abstract][Full Text] [Related]
45. [Efficacy of combination therapy with pegylated-interferon alfa-2a plus ribavirin in autoantibody-positive chronic hepatitis C patients].
Li YX; Yang YJ; Yang M; Chen LY; Lu JJ; Ma YJ; Liu K; Lei XZ; Tang H
Zhonghua Gan Zang Bing Za Zhi; 2013 May; 21(5):345-7. PubMed ID: 24025134
[TBL] [Abstract][Full Text] [Related]
46. [Association between ribavirin plasma concentration and sustained virologic response in treatment of patients with genotype 1b chronic hepatitis C with pegylated interferon-α-2b and ribavirin].
Wang MR; Zhang X; Yang ZG; Li P; Gao L; Chen XH; Wang J; Xiong X; Wang SM; Geng JB; Hao KY; Xie F; Wang M; Zheng WK
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):175-80. PubMed ID: 27095759
[TBL] [Abstract][Full Text] [Related]
47. A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA; Gonzalez-Colominas E; García-Retortillo M; Cañete N; Cirera I; Coll S; Giménez MD; Márquez C; Martin-Escudero V; Castellví P; Navinés R; Castaño JR; Galeras JA; Salas E; Bory F; Martín-Santos R; Solà R
J Hepatol; 2013 Nov; 59(5):926-33. PubMed ID: 23811030
[TBL] [Abstract][Full Text] [Related]
48. Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan.
Lin JA; Chen YC; Cheng SN; Chen PJ; Chu HC; Hsieh TY; Shih YL
J Formos Med Assoc; 2014 Oct; 113(10):727-33. PubMed ID: 24231092
[TBL] [Abstract][Full Text] [Related]
49. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
50. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
[TBL] [Abstract][Full Text] [Related]
51. Long-term outcomes of thyroid dysfunction in patients with chronić hepatitis C treated with pegylated interferon alpha and ribavirin.
Kozielewicz D; Wietlicka-Piszcz M; Halota W
Przegl Epidemiol; 2017; 71(4):555-569. PubMed ID: 29415534
[TBL] [Abstract][Full Text] [Related]
52. Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin.
Ng KJ; Tseng CW; Chang TT; Tzeng SJ; Hsieh YH; Hung TH; Huang HT; Wu SF; Tseng KC
Clin Interv Aging; 2016; 11():1035-41. PubMed ID: 27536084
[TBL] [Abstract][Full Text] [Related]
53. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
[TBL] [Abstract][Full Text] [Related]
54. Pegylated interferon plus ribavirin therapy improves pancreatic β-cell function in chronic hepatitis C patients.
Huang JF; Dai CY; Yu ML; Huang CF; Huang CI; Yeh ML; Yang JF; Hou NJ; Hsiao PJ; Lin ZY; Chen SC; Shin SJ; Chuang WL
Liver Int; 2011 Sep; 31(8):1155-62. PubMed ID: 21745292
[TBL] [Abstract][Full Text] [Related]
55. Human leukocyte antigen alleles and the response to pegylated interferon/ribavirin therapy in chronic hepatitis C patients.
Dai CY; Chuang WL; Hsieh MY; Huang JF; Lin YY; Chu PY; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
Antiviral Res; 2010 Feb; 85(2):396-402. PubMed ID: 19931565
[TBL] [Abstract][Full Text] [Related]
56. Treatment of patients with dual hepatitis C and B by peginterferon α and ribavirin reduced risk of hepatocellular carcinoma and mortality.
Liu CJ; Chu YT; Shau WY; Kuo RN; Chen PJ; Lai MS
Gut; 2014 Mar; 63(3):506-14. PubMed ID: 23676440
[TBL] [Abstract][Full Text] [Related]
57. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
Butt AA; Yan P; Aslam S; Shaikh OS; Abou-Samra AB
Clin Infect Dis; 2020 Mar; 70(6):1153-1160. PubMed ID: 30977808
[TBL] [Abstract][Full Text] [Related]
58. [Genomic diversity of the genotype 1b hepatitis C virus open reading frame is correlated with outcomes of combined pegylated-interferon/ribavirin therapy in patients with chronic hepatitis C from Henan Province].
Zeng Y; Kang Y; Shang J
Zhonghua Gan Zang Bing Za Zhi; 2014 Jun; 22(6):401-6. PubMed ID: 25203700
[TBL] [Abstract][Full Text] [Related]
59. Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.
Stättermayer AF; Strassl R; Maieron A; Rutter K; Stauber R; Strasser M; Beinhardt S; Datz C; Scherzer TM; Steindl-Munda P; Gschwantler M; Trauner M; Hofer H; Ferenci P
Aliment Pharmacol Ther; 2014 Jan; 39(1):104-11. PubMed ID: 24205831
[TBL] [Abstract][Full Text] [Related]
60. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]